Image source: FACIT

Facit’s Prospects Fund Fuels Women’s Health and Brain Cancer Therapies for Ontario Patients

Seed-stage commercialization realizes value in the Province’s health research and intellectual property.

September 28, 2022 – FACIT congratulates Ontario-based start-ups Hyivy Health and HDAX Therapeutics as the latest recipients of capital through its Prospects Oncology Fund. Selected among a top-tier pool of applicants, these Ontario-based innovations illustrate excellent potential to benefit patients with cancer.

Former Falcons’ Fortunes pitch competition finalist Hyivy Health is developing a remote patient monitoring, pelvic rehab system for gynecological and colorectal cancer patients and their clinicians. Prospects funding will support a clinical trial currently in protocol development at Grand River Regional Cancer Centre in Kitchener, Ontario. A spin-off from the University of Toronto, HDAX Therapeutics is developing potentially first-in-class, blood-brain barrier permeable HDAC6 selective inhibitors for CNS cancers. Prospects funding will accelerate CTA/IND enabling research and preparation for clinical studies.

Read the original article.

Metadata
Share this article!
image promoting launch event featuring women attending an event and smiling

Celebrate the official launch of Femtech Canada

Please join Femtech Canada on January 17th, 2024 and connect with the femtech community that is shaping the future of women’s health!

Our website uses cookies to ensure you get the best experience. Learn More